The Best Thinking: Epidemiology
Every indication has been reviewed exhaustively for the most current, robust epidemiology and relevant natural history (e.g., survival, comorbidities).
Clients have full view of included and excluded sources with documentation for inclusion/exclusion criteria.
Population & Treatment Factors
Population, growth, diagnosis & treatment rate assumptions based on input from KOLs and relevant peer-reviewed literature are provided to provide context for the forecasts. Forecasts are reported at sub-type granularity where applicable.
Factors are fully transparent to ensure Client has full utility and understanding of estimates & forecasts in a rapidly developing technological landscape.
Competition: Tracking Development
BluePrint Orphan actively maintains a database tracking the development of all molecules pursuing an Orphan indication across all phases of approval, globally.
Clients have full insight into our assessment of each target's value proposition, and how launch timing & value relative to competitors impacts the forecast.
Pricing, Reimbursement, & Evolving Access
Experience, analogue data, and a panel of key opinion leaders helps inform pricing, reimbursement, and market access assumptions within each therapeutic category at the US & Global levels. Launch timing assumptions and downstream access & pricing impacts are provided for context.